DCLK3 and neoplasm: Hence, the tumor glyco-code becomes a promising novel immune checkpoint harnessable for cancer immunotherapy in multiple ways (17): anti-glycan vaccines aiming at inducing specific anti-glycan immune responses, blocking glycans/lectins interactions, or DC targeting through CLR with glycan-coupled tumor antigens.